Ethic Inc. Takes Position in Charles River Laboratories International, Inc. $CRL

Key Points

• Ethic Inc. purchased a new stake in Charles River Laboratories International, Inc. valued at approximately $523,000 during the first quarter, acquiring 3,584 shares.
• Several institutional investors significantly increased their positions in CRL; for instance, Rothschild Investment LLC boosted their stake by 480% in the same quarter.
• Charles River Laboratories reported $3.12 EPS in its latest quarterly results, surpassing analysts' expectations of $2.50, with a revenue of $1.03 billion.

Ethic Inc. bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 3,584 shares of the medical research company's stock, valued at approximately $523,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in Charles River Laboratories International by 7.2% during the first quarter. Invesco Ltd. now owns 1,108,358 shares of the medical research company's stock worth $166,830,000 after acquiring an additional 74,178 shares in the last quarter. Ariel Investments LLC lifted its holdings in Charles River Laboratories International by 18.9% during the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after acquiring an additional 169,640 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in Charles River Laboratories International by 2.6% during the first quarter. Mackenzie Financial Corp now owns 1,002,951 shares of the medical research company's stock worth $150,964,000 after acquiring an additional 25,878 shares in the last quarter. D1 Capital Partners L.P. bought a new position in Charles River Laboratories International during the fourth quarter worth about $172,752,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Charles River Laboratories International by 30.0% during the first quarter. Dimensional Fund Advisors LP now owns 862,254 shares of the medical research company's stock worth $129,799,000 after acquiring an additional 198,750 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares of the company's stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Performance

NYSE CRL traded down $1.05 during trading on Wednesday, reaching $162.66. 417,347 shares of the company's stock were exchanged, compared to its average volume of 955,117. The business has a 50 day moving average price of $158.64 and a 200-day moving average price of $148.73. The stock has a market capitalization of $8.00 billion, a P/E ratio of -122.30, a PEG ratio of 5.22 and a beta of 1.48. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business's revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.80 earnings per share. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on CRL. Wall Street Zen lowered Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 17th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Evercore ISI boosted their price target on Charles River Laboratories International from $180.00 to $190.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and upped their target price for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Finally, TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a report on Wednesday, May 14th. Five equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and an average target price of $175.69.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).